Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D1O9XQ
|
|||
| Drug Name |
SKY59
|
|||
| Synonyms |
Crovalimab; RO7112689
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Haemolytic uraemic syndrome [ICD-11: 3A21.2; ICD-10: D59.3] | Phase 3 | [1] | |
| Company |
Roche
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Complement C5 (CO5) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Prion diseases | ||||
| Pertussis | ||||
| Staphylococcus aureus infection | ||||
| Herpes simplex infection | ||||
| Systemic lupus erythematosus | ||||
| Reactome | Activation of C3 and C5 | |||
| Peptide ligand-binding receptors | ||||
| G alpha (i) signalling events | ||||
| Regulation of Complement cascade | ||||
| WikiPathways | Complement Activation, Classical Pathway | |||
| Human Complement System | ||||
| Spinal Cord Injury | ||||
| Allograft Rejection | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Complement cascade | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04861259) A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) (COMMUTE-a). U.S. National Institutes of Health. | |||
| REF 2 | The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood. 2020 Mar 19;135(12):912-920. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.